Brisbane-based startup TeleMedC is rolling out RetinoScan, a diagnostic platform for diabetic retinopathy (DR), glaucoma and age-related macular degeneration (AMD), to 150 Australian general practices in 2023.
The artificial intelligence (AI) -powered triaging tool is simple to use and can be operated by GPs and ophthalmic assistants with basic training, according to the company. RetinoScan offers 97% sensitivity and 92% specificity for DR detection and is accompanied by a mobile app, EyeQx, allowing patients to access their screening results and receive referrals to specialists for continuous care.
While general practice is the cornerstone of health, only ophthalmologists and optometrists routinely examine the retina, read a company statement. “Our EyeQx primary care intervention programme is led by eye health professionals to deliver quality-assured services.”
RetinoScan is a class-2 medical device approved by the Australian Therapeutic Goods Administration, is ISO and CE certified and is awaiting approval from the US Food and Drug Administration.
